DaVita(DVA) - 2022 Q4 - Earnings Call Transcript

Andrew Mok with UBS. Andrew Mok Great. Just a few numbers questions to follow up. Your D&A increased about $20 million sequentially. Is that from the new clinical IT investments? Or is there something else driving that DNA higher in the quarter? Is that a good number to think about for 2023 from a run rate perspective? Joel Ackerman Yes. I think modeling consolidated D&A for 2023, I'd say we don't expect that to change very much from the full year 2022. Andrew Mok So D&A will be flat even though it ticked u ...